BRAF Mutation Analysis by PCR
Use
This PCR‑based assay detects BRAF V600 mutations including V600E, K, D, R, and G. It is intended for solid tumor testing where tumor enrichment is performed prior to DNA extraction. Detection of these mutations informs oncologists regarding eligibility for targeted therapies and complements expanded coverage available in the RAS/RAF Panel when ordered in combination. Expanded coverage includes BRAF exons 11 and 15. The assay thus plays a role in guiding molecular‐targeted therapeutic decision‑making.
Special Instructions
For solid tumors, tumor enrichment is required before extraction. Expanded coverage for BRAF exons 11 & 15 is available via the RAS/RAF Panel (which includes HRAS, KRAS, NRAS). Test may be ordered separately or combined. If specimen hold service is desired, select “Extract & Hold – DNA.”
Limitations
Not provided.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin block or slides
Collection Instructions
FFPE solid tumor tissue: paraffin block preferred. Alternatively send 1 H&E slide plus 5‑10 unstained slides cut at ≥5 µm, on positively‑charged slides, fixed in 10% NBF (do not use zinc fixatives). Peripheral blood: 5 mL in EDTA tube. Bone marrow: 2 mL in EDTA tube.
Storage Instructions
Use cold pack for transport, not in direct contact with specimen. NYS clients: provide date and time of collection.